Bioventus Reaffirms 2026 Guidance and Discusses Strategic Alternatives
Bioventus (BVS) has reaffirmed its financial outlook for 2026, projecting revenue between $590 million and $595 million alongside adjusted earnings per share (EPS) in the range of $0.75 to $0.79. Management noted that the company is maintaining steady momentum following its third-quarter performance. In addition to financial guidance, CEO Robert Claypoole confirmed that the company's previously disclosed strategic review process remains active. Bioventus is currently working with external advisers to evaluate various strategic options for the business.
Tickers: $BVS